A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Status:
Not yet recruiting

Trial end date:
2025-05-03

Target enrollment:

Participant gender:

The main objective of this study is to evaluate the safety and tolerability of bemarituzumab in combination with other anti-cancer therapies.

Phase 1

Amgen

Bemarituzumab
Nivolumab